Trial Profile
A Phase 1, Multiple Ascending Dose, Glucose Clamp Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM12460A Compared to Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2021
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Hanmi Pharmaceutical
- 11 Aug 2020 Planned End Date changed from 30 Sep 2019 to 30 Sep 2020.
- 20 Sep 2019 Planned End Date changed from 30 Jun 2019 to 30 Sep 2019.
- 20 Sep 2019 Status changed from discontinued to suspended.